Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus ERYTHROMYCIN ESTOLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus ERYTHROMYCIN ESTOLATE.
E.E.S. 200 vs ERYTHROMYCIN ESTOLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
250-500 mg orally every 6-12 hours
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic